ロード中...
Cost-effectiveness of Pembrolizumab as a Second-Line Therapy for Hepatocellular Carcinoma
IMPORTANCE: Immune checkpoint inhibitors have been approved for use as a second-line therapy for hepatocellular carcinoma (HCC) in patients who previously received sorafenib. Pembrolizumab has shown substantial antitumor activity and a favorable toxicity profile as a second-line treatment of HCC. Ho...
保存先:
| 出版年: | JAMA Netw Open |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
American Medical Association
2021
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7816108/ https://ncbi.nlm.nih.gov/pubmed/33464318 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamanetworkopen.2020.33761 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|